Literature DB >> 3918108

Increase in cytosolic free calcium concentration is an intracellular messenger for the production of interleukin 2 but not for expression of the interleukin 2 receptor.

G B Mills, R K Cheung, S Grinstein, E W Gelfand.   

Abstract

Activation of lymphocytes by mitogenic lectins results in the production of a group of soluble factors, the lymphokines. Proliferation of activated T cells requires interaction of one of these lymphokines, interleukin 2 (IL 2), with its receptor. The induction of IL 2 receptor expression and IL 2 production may involve different activation signals; some mitogens or antigens may activate both, whereas others may activate only one. An increase in cytosolic free calcium concentrations [( Ca++]i) is one of the signals involved in cellular activation by lectins. By using the fluorescent indicator quin-2, we have demonstrated that increases in [Ca++]i accompany phytohemagglutinin induced proliferative responses of human T lymphocytes. Preventing the increase in [Ca++]i also prevents proliferation. We demonstrate that an increase in [Ca++]i is not required for the expression of the IL 2 receptor, which is expressed even in the presence of extremely low external calcium concentrations. In contrast, IL 2 production requires an increase in [Ca++]i and does not occur in the absence of extracellular free calcium. IL 2 production appears to be the critical step requiring transmembrane calcium flux. In the absence of transmembrane calcium flux and subsequent IL 2 production, lectins are not able to trigger DNA synthesis and cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3918108

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Transcription of two cytotoxic cell protease genes is under the control of different regulatory elements.

Authors:  C J Frégeau; R C Bleackley
Journal:  Nucleic Acids Res       Date:  1991-10-25       Impact factor: 16.971

2.  Regulation of IL-4 lymphokine gene expression and cellular proliferation in murine T helper type II cells.

Authors:  E Muñoz; A M Zubiaga; J Muñoz; B T Huber
Journal:  Cell Regul       Date:  1990-04

3.  Synergism between AS101 and PMA in lymphokine production.

Authors:  B Sredni; Y Kalechman; F Shalit; M Albeck
Journal:  Immunology       Date:  1990-01       Impact factor: 7.397

4.  Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives.

Authors:  M Schleuning; V Brumme; W Wilmanns
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

5.  Decreased lymphocyte blastogenesis, IL2 production and NK activity following nifedipine administration to healthy humans.

Authors:  A Morgano; I Pierri; R Stagnaro; M Setti; F Puppo; F Indiveri
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 6.  Regulation of T cell activation by leukotriene B4.

Authors:  J S Goodwin
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

7.  Transcriptional regulation of two cytotoxic T lymphocyte-specific serine protease genes.

Authors:  C G Lobe; J Shaw; C Fregeau; B Duggan; M Meier; A Brewer; C Upton; G McFadden; R K Patient; V Paetkau
Journal:  Nucleic Acids Res       Date:  1989-07-25       Impact factor: 16.971

8.  Functional heterogeneity in the process of T lymphocyte activation; barium blocks several modes of T cell activation, but spares a functionally unique subset of PHA-activable T cells.

Authors:  L T Peçanha; G A Dos Reis
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

9.  Verapamil ameliorates the clinical and pathological course of murine myocarditis.

Authors:  R Dong; P Liu; L Wee; J Butany; M J Sole
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

10.  IL-2 regulation of soluble IL-2 receptor levels following thermal injury.

Authors:  J A Teodorczyk-Injeyan; B G Sparkes; S Lalani; W J Peters; G B Mills
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.